KPV (10mg)
KPV (Lysine–Proline–Valine) is a C-terminal tripeptide segment of α-melanocyte-stimulating hormone (α-MSH) that is studied for its potent anti-inflammatory properties without melanotropic side effects. Research indicates that KPV reduces pro-inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation. This protocol outlines a once-daily subcutaneous approach.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
KPV is the C-terminal tripeptide sequence (amino acids 11–13) of α-melanocyte-stimulating hormone (α-MSH), which retains potent anti-inflammatory activity without melanotropic effects. Preclinical studies show that KPV reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and regulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. The mechanism involves inhibition of NF-κB signaling and regulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 200–500 mcg once daily (gradual titration).
- Storage: Lyophilized: freezer −20 °C; after reconstitution, refrigerator 2–8 °C; use within 30 days; avoid freeze-thaw cycles.
Typical / Gradual Approach (3 mL = ~3.33 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Week 1 | 200 mcg | 6 Units (0.06 mL) |
| Week 2 | 300 mcg | 9 Units (0.09 mL) |
| Week 3 | 400 mcg | 12 Units (0.12 mL) |
| Weeks 4–8 | 500 mcg | 15 Units (0.15 mL) |
Studies report administration once daily subcutaneously.
Related compounds
Reconstitution Steps
- Withdraw 3.0 mL of bacteriostatic water.
- Slowly inject against the wall; avoid foaming.
- Gently swirl/rotate until dissolved (do not shake).
- Label and refrigerate at 2–8 °C, protecting from light.
Protocol Overview
- Objective: Support the reduction of systemic inflammation and regulation of immune responses without melanotropic effects.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16 wks).
- Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated; avoid freeze-thaw cycles.
Dosing Protocol
- Start: 200 mcg daily; increase by ~100 mcg weekly.
- Target: 400–500 mcg daily by Wk 4–8 for anti-inflammatory maintenance.
- Frequency: Once daily subcutaneously.
- Cycle Duration: 8–12 weeks; optional extension to 16 wks.
- Timing: Consistent time daily; rotate sites.
- Break between cycles: After the cycle (8–16 weeks), a 2–4 week pause is recommended. KPV is anti-inflammatory—the pause helps prevent potential immunosuppression.
Washout & Cycle Restart
When can I restart?
After the cycle (8–16 weeks), a 2–4 week pause is recommended. KPV is anti-inflammatory—the pause helps prevent potential immunosuppression.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C; use within ~30 days.
- Allow vials to reach room temperature before opening.
- Avoid freeze-thaw cycles.
Important Notes
- For site reactions (redness, mild swelling), apply a cool compress.
Potential Benefits & Side Effects
Potential Benefits:
- Anti-inflammatory action: Reduction of pro-inflammatory cytokines in models of inflammatory bowel disease.
- Oral & subcutaneous efficacy: Multiple administration routes show activity.
- Wound healing support: Preclinical data suggests it may support tissue repair.
- Generally well-tolerated: Occasional mild injection site reactions.
- No melanotropic effects: Unlike full α-MSH, it does not affect skin pigmentation.
Potential Side Effects:
- Occasional mild injection site reactions (redness, slight swelling).
- Systemic side effects are rarely reported in research protocols.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Immunosuppression with chronic use
KPV (α-MSH fragment) is strongly anti-inflammatory. Theoretical risk of reduced immune surveillance with long-term use. No clinical studies in humans.
📄 FEBS Lett 2005References
- J Pharm Drug Deliv Res (2022) — KPV as a fragment of α-MSH: potent anti-inflammatory action
View Source - FASEB Journal (2003) — α-MSH and tripeptides: regulation of colitis and inflammation
View Source - Gastroenterology (2008) — PepT1-mediated uptake of KPV reduces intestinal inflammation
View Source - Innerbody Research (2025) — KPV peptide: benefits, safety, and routes of administration
View Source - Peptides.org (2023) — KPV dosage: 200–400 mcg subcutaneously daily
View Source
Recommended Supplements
Curcumin (Turmeric Extract)
Collagen Peptides
External Sources & Regulatory Status
Regulatory Approvals
Research-only — α-MSH derivative
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →